Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 9
2012 25
2013 70
2014 155
2015 271
2016 324
2017 413
2018 460
2019 503
2020 541
2021 585
2022 512
2023 459
2024 158

Text availability

Article attribute

Article type

Publication date

Search Results

3,895 results

Results by year

Filters applied: . Clear all
Page 1
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. Honigberg LA, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6. Proc Natl Acad Sci U S A. 2010. PMID: 20615965 Free PMC article.
PCI-32765 also inhibited autoantibody production and the development of kidney disease in the MRL-Fas(lpr) lupus model. Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk. ...
PCI-32765 also inhibited autoantibody production and the development of kidney disease in the MRL-Fas(lpr) lupus model. Occupa …
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
Jain N, O'Brien S. Jain N, et al. Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006. Hematol Oncol Clin North Am. 2013. PMID: 23915749 Free PMC article. Review.
Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. Ibrutinib (PCI-32765) is a novel first-in-class selective inhibitor of Bruton tyrosine kinase. Preclinical evidence suggests that ibrutinib inhibits CLL cell …
Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. Ibrutinib (PCI-32765) is …
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Winer ES, Ingham RR, Castillo JJ. Winer ES, et al. Expert Opin Investig Drugs. 2012 Mar;21(3):355-61. doi: 10.1517/13543784.2012.656199. Epub 2012 Feb 3. Expert Opin Investig Drugs. 2012. PMID: 22300471 Review.
AREAS COVERED: This review will summarize the current knowledge of the Btk pathway and its role in lymphoid malignancies. It will also discuss the present data about PCI-32765 in both the preclinical and clinical setting. EXPERT OPINION: PCI-32765 is a …
AREAS COVERED: This review will summarize the current knowledge of the Btk pathway and its role in lymphoid malignancies. It will also discu …
Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
Brown JR. Brown JR. Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. doi: 10.1007/s11899-012-0147-9. Curr Hematol Malig Rep. 2013. PMID: 23296407 Free PMC article. Review.
Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment. ...The ORR of ibrutinib in relapsed refractory CLL is 67 % with PFS 88 % at 15 months. ...
Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment. ...The ORR of …
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Burger JA, Buggy JJ. Burger JA, et al. Leuk Lymphoma. 2013 Nov;54(11):2385-91. doi: 10.3109/10428194.2013.777837. Epub 2013 Aug 28. Leuk Lymphoma. 2013. PMID: 23425038 Review.
Over the past 3 years, ibrutinib (PCI-32765) has emerged as a breakthrough in targeted therapy for patients with certain types of B cell malignancies. ...This review discusses the discovery, preclinical and clinical development of ibrutinib, its pathop …
Over the past 3 years, ibrutinib (PCI-32765) has emerged as a breakthrough in targeted therapy for patients with certai …
Management of adverse effects/toxicity of ibrutinib.
Paydas S. Paydas S. Crit Rev Oncol Hematol. 2019 Apr;136:56-63. doi: 10.1016/j.critrevonc.2019.02.001. Epub 2019 Feb 10. Crit Rev Oncol Hematol. 2019. PMID: 30878129 Review.
Ibrutinib has been approved by FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, marginal zone lymphoma and chronic graft-versus-host disease in allogeneic stem cell transplantation. Ibrutinib is generally …
Ibrutinib has been approved by FDA for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobul …
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Barr PM, et al. Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434. Blood Adv. 2022. PMID: 35377947 Free PMC article. Clinical Trial.
OS at 7 years was 78% with ibrutinib. Prevalence of adverse events (AEs) was consistent with previous 5-year follow-up. ...With up to 8 years of follow-up, 42% of patients remain on ibrutinib. Long-term RESONATE-2 data demonstrate sustained benefit with first-line …
OS at 7 years was 78% with ibrutinib. Prevalence of adverse events (AEs) was consistent with previous 5-year follow-up. ...With up to …
Ibrutinib.
[No authors listed] [No authors listed] 2022 Jun 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Jun 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999910 Free Books & Documents. Review.
No information is available on the clinical use of ibrutinib during breastfeeding. Because ibrutinib is more than 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ibrutinib …
No information is available on the clinical use of ibrutinib during breastfeeding. Because ibrutinib is more than 97% bound to …
Ibrutinib.
Schwarzbich MA, Witzens-Harig M. Schwarzbich MA, et al. Recent Results Cancer Res. 2014;201:259-67. doi: 10.1007/978-3-642-54490-3_17. Recent Results Cancer Res. 2014. PMID: 24756799 Review.
Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. ...This chapter discusses structure, mechanism of action, and toxicities of ibrutinib a …
Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves …
Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression.
Li W, Ali T, He K, Liu Z, Shah FA, Ren Q, Liu Y, Jiang A, Li S. Li W, et al. Brain Behav Immun. 2021 Feb;92:10-24. doi: 10.1016/j.bbi.2020.11.008. Epub 2020 Nov 10. Brain Behav Immun. 2021. PMID: 33181270
Therefore, we aimed to elucidate the potential anti-depressive role and mechanism of ibrutinib against neuroinflammation-induced depression and synaptic defects. ...Further, ibrutinib treatment inhibited LPS-activated inflammasome activation by targeting NLRP3/P38/C …
Therefore, we aimed to elucidate the potential anti-depressive role and mechanism of ibrutinib against neuroinflammation-induced depr …
3,895 results